Drugs / Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
also known as
MenACYW conjugate vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02842853 | Jul 2016 → Feb 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02842853 ↗ |
| Known as | MenACYW conjugate vaccine | “MenACYW conjugate vaccine” NCT02842853 ↗ |
| Modality | Vaccine | “Meningococcal Conjugate Vaccine” NCT02842853 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT02842853 ↗ |